KT2 showed lower mutation burden compared to KIRC and KIRP (Fig. 5b) and did not display the typical kidney cancer genetic lesions, nor mutations in TP53, a tumor suppressor often mutated in pre-cancer clones in human tissues [7, 8, 10] (Additional file 1: Table S5). This evidence concerns the gene TP53 and neoplasm.